nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—ABCB1—colon cancer	0.458	1	CbGaD
Loperamide—CYP2B6—Irinotecan—colon cancer	0.0497	0.283	CbGbCtD
Loperamide—CYP2C8—Fluorouracil—colon cancer	0.0362	0.206	CbGbCtD
Loperamide—ABCB1—Irinotecan—colon cancer	0.0255	0.145	CbGbCtD
Loperamide—Megacolon toxic—Irinotecan—colon cancer	0.0228	0.144	CcSEcCtD
Loperamide—ABCB1—Vincristine—colon cancer	0.0223	0.127	CbGbCtD
Loperamide—CYP3A4—Irinotecan—colon cancer	0.0153	0.0869	CbGbCtD
Loperamide—Abdominal colic—Vincristine—colon cancer	0.0144	0.0912	CcSEcCtD
Loperamide—ABCB1—Methotrexate—colon cancer	0.0135	0.0768	CbGbCtD
Loperamide—CYP3A4—Vincristine—colon cancer	0.0134	0.076	CbGbCtD
Loperamide—Megacolon—Irinotecan—colon cancer	0.0116	0.0732	CcSEcCtD
Loperamide—Megacolon toxic—Methotrexate—colon cancer	0.0113	0.0718	CcSEcCtD
Loperamide—POMC—blood vessel—colon cancer	0.00986	0.117	CbGeAlD
Loperamide—Megacolon—Methotrexate—colon cancer	0.00576	0.0365	CcSEcCtD
Loperamide—Ileus paralytic—Vincristine—colon cancer	0.00451	0.0285	CcSEcCtD
Loperamide—POMC—renal system—colon cancer	0.00445	0.0528	CbGeAlD
Loperamide—Altered state of consciousness—Vincristine—colon cancer	0.00422	0.0267	CcSEcCtD
Loperamide—POMC—lymphoid tissue—colon cancer	0.0037	0.0438	CbGeAlD
Loperamide—POMC—digestive system—colon cancer	0.00365	0.0433	CbGeAlD
Loperamide—POMC—vagina—colon cancer	0.00322	0.0382	CbGeAlD
Loperamide—Ileus paralytic—Capecitabine—colon cancer	0.00294	0.0186	CcSEcCtD
Loperamide—CALM2—endothelium—colon cancer	0.00292	0.0346	CbGeAlD
Loperamide—CALM1—endothelium—colon cancer	0.00291	0.0345	CbGeAlD
Loperamide—Abdominal cramps—Vincristine—colon cancer	0.00289	0.0183	CcSEcCtD
Loperamide—Abdominal cramps—Irinotecan—colon cancer	0.00281	0.0178	CcSEcCtD
Loperamide—Ileus—Vincristine—colon cancer	0.00275	0.0174	CcSEcCtD
Loperamide—Altered state of consciousness—Capecitabine—colon cancer	0.00275	0.0174	CcSEcCtD
Loperamide—POMC—liver—colon cancer	0.00272	0.0323	CbGeAlD
Loperamide—CALM2—blood vessel—colon cancer	0.00269	0.0319	CbGeAlD
Loperamide—Ileus—Irinotecan—colon cancer	0.00268	0.017	CcSEcCtD
Loperamide—CALM1—blood vessel—colon cancer	0.00268	0.0318	CbGeAlD
Loperamide—CALM2—gall bladder—colon cancer	0.00253	0.03	CbGeAlD
Loperamide—OPRD1—renal system—colon cancer	0.00246	0.0291	CbGeAlD
Loperamide—Ileus—Capecitabine—colon cancer	0.00179	0.0114	CcSEcCtD
Loperamide—CALM3—smooth muscle tissue—colon cancer	0.00161	0.0191	CbGeAlD
Loperamide—CALM2—embryo—colon cancer	0.00161	0.019	CbGeAlD
Loperamide—CALM1—embryo—colon cancer	0.0016	0.019	CbGeAlD
Loperamide—Anaphylactoid reaction—Irinotecan—colon cancer	0.00142	0.00901	CcSEcCtD
Loperamide—Dermatitis bullous—Fluorouracil—colon cancer	0.00138	0.00874	CcSEcCtD
Loperamide—Urinary retention—Vincristine—colon cancer	0.00135	0.00851	CcSEcCtD
Loperamide—CALM2—epithelium—colon cancer	0.00131	0.0155	CbGeAlD
Loperamide—CALM1—epithelium—colon cancer	0.0013	0.0155	CbGeAlD
Loperamide—CALM2—smooth muscle tissue—colon cancer	0.00126	0.015	CbGeAlD
Loperamide—CALM1—smooth muscle tissue—colon cancer	0.00126	0.0149	CbGeAlD
Loperamide—Depressed level of consciousness—Capecitabine—colon cancer	0.00123	0.00776	CcSEcCtD
Loperamide—CALM2—renal system—colon cancer	0.00122	0.0144	CbGeAlD
Loperamide—CALM1—renal system—colon cancer	0.00121	0.0144	CbGeAlD
Loperamide—Abdominal distension—Irinotecan—colon cancer	0.0012	0.00759	CcSEcCtD
Loperamide—CALM3—bone marrow—colon cancer	0.00117	0.0139	CbGeAlD
Loperamide—CALM3—vagina—colon cancer	0.00112	0.0133	CbGeAlD
Loperamide—ABCB1—blood vessel—colon cancer	0.00107	0.0127	CbGeAlD
Loperamide—CALM2—lymphoid tissue—colon cancer	0.00101	0.012	CbGeAlD
Loperamide—CYP2C8—renal system—colon cancer	0.00101	0.0119	CbGeAlD
Loperamide—CALM1—lymphoid tissue—colon cancer	0.001	0.0119	CbGeAlD
Loperamide—CALM2—digestive system—colon cancer	0.000997	0.0118	CbGeAlD
Loperamide—CALM1—digestive system—colon cancer	0.000993	0.0118	CbGeAlD
Loperamide—Urinary tract disorder—Vincristine—colon cancer	0.000966	0.00612	CcSEcCtD
Loperamide—Dermatitis bullous—Capecitabine—colon cancer	0.000965	0.00611	CcSEcCtD
Loperamide—Urethral disorder—Vincristine—colon cancer	0.000959	0.00607	CcSEcCtD
Loperamide—CALM3—liver—colon cancer	0.000946	0.0112	CbGeAlD
Loperamide—CALM2—bone marrow—colon cancer	0.000919	0.0109	CbGeAlD
Loperamide—CALM1—bone marrow—colon cancer	0.000915	0.0108	CbGeAlD
Loperamide—Depressed level of consciousness—Methotrexate—colon cancer	0.000913	0.00578	CcSEcCtD
Loperamide—CYP2B6—renal system—colon cancer	0.000904	0.0107	CbGeAlD
Loperamide—CALM2—vagina—colon cancer	0.000881	0.0104	CbGeAlD
Loperamide—Urinary retention—Capecitabine—colon cancer	0.000877	0.00555	CcSEcCtD
Loperamide—CALM1—vagina—colon cancer	0.000877	0.0104	CbGeAlD
Loperamide—Immune system disorder—Irinotecan—colon cancer	0.000861	0.00545	CcSEcCtD
Loperamide—Abdominal pain upper—Capecitabine—colon cancer	0.000842	0.00533	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.00083	0.00526	CcSEcCtD
Loperamide—Flatulence—Irinotecan—colon cancer	0.000817	0.00518	CcSEcCtD
Loperamide—Abdominal distension—Capecitabine—colon cancer	0.000802	0.00508	CcSEcCtD
Loperamide—CYP2B6—lymphoid tissue—colon cancer	0.000751	0.0089	CbGeAlD
Loperamide—CALM2—liver—colon cancer	0.000743	0.00881	CbGeAlD
Loperamide—CYP2B6—digestive system—colon cancer	0.000741	0.00879	CbGeAlD
Loperamide—CALM1—liver—colon cancer	0.00074	0.00877	CbGeAlD
Loperamide—CYP2C8—vagina—colon cancer	0.00073	0.00865	CbGeAlD
Loperamide—Loss of consciousness—Irinotecan—colon cancer	0.000729	0.00462	CcSEcCtD
Loperamide—CALM3—lymph node—colon cancer	0.000725	0.0086	CbGeAlD
Loperamide—Anaphylactoid reaction—Methotrexate—colon cancer	0.000709	0.00449	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000704	0.00446	CcSEcCtD
Loperamide—Discomfort—Irinotecan—colon cancer	0.000698	0.00442	CcSEcCtD
Loperamide—Anaphylactic shock—Vincristine—colon cancer	0.000695	0.0044	CcSEcCtD
Loperamide—CYP3A4—renal system—colon cancer	0.000683	0.00809	CbGeAlD
Loperamide—Nervous system disorder—Vincristine—colon cancer	0.000682	0.00432	CcSEcCtD
Loperamide—Anaphylactic shock—Irinotecan—colon cancer	0.000677	0.00429	CcSEcCtD
Loperamide—CYP2D6—renal system—colon cancer	0.000672	0.00796	CbGeAlD
Loperamide—Discomfort—Fluorouracil—colon cancer	0.000668	0.00423	CcSEcCtD
Loperamide—Nervous system disorder—Irinotecan—colon cancer	0.000664	0.0042	CcSEcCtD
Loperamide—CYP2B6—vagina—colon cancer	0.000655	0.00776	CbGeAlD
Loperamide—Anaphylactic shock—Fluorouracil—colon cancer	0.000648	0.00411	CcSEcCtD
Loperamide—ABCB1—embryo—colon cancer	0.000638	0.00757	CbGeAlD
Loperamide—Nervous system disorder—Fluorouracil—colon cancer	0.000636	0.00403	CcSEcCtD
Loperamide—Urinary tract disorder—Capecitabine—colon cancer	0.00063	0.00399	CcSEcCtD
Loperamide—Urethral disorder—Capecitabine—colon cancer	0.000625	0.00396	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000618	0.00391	CcSEcCtD
Loperamide—CYP2C8—liver—colon cancer	0.000616	0.0073	CbGeAlD
Loperamide—Erythema multiforme—Capecitabine—colon cancer	0.000603	0.00382	CcSEcCtD
Loperamide—Somnolence—Irinotecan—colon cancer	0.000602	0.00381	CcSEcCtD
Loperamide—Gastrointestinal disorder—Vincristine—colon cancer	0.0006	0.0038	CcSEcCtD
Loperamide—Fatigue—Vincristine—colon cancer	0.000599	0.00379	CcSEcCtD
Loperamide—Dyspepsia—Irinotecan—colon cancer	0.000596	0.00377	CcSEcCtD
Loperamide—Constipation—Vincristine—colon cancer	0.000595	0.00376	CcSEcCtD
Loperamide—Gastrointestinal disorder—Irinotecan—colon cancer	0.000585	0.0037	CcSEcCtD
Loperamide—Fatigue—Irinotecan—colon cancer	0.000584	0.0037	CcSEcCtD
Loperamide—Constipation—Irinotecan—colon cancer	0.000579	0.00367	CcSEcCtD
Loperamide—Somnolence—Fluorouracil—colon cancer	0.000576	0.00365	CcSEcCtD
Loperamide—Immune system disorder—Capecitabine—colon cancer	0.000576	0.00365	CcSEcCtD
Loperamide—Dyspepsia—Fluorouracil—colon cancer	0.000571	0.00361	CcSEcCtD
Loperamide—CALM2—lymph node—colon cancer	0.00057	0.00675	CbGeAlD
Loperamide—Gastrointestinal pain—Vincristine—colon cancer	0.000569	0.0036	CcSEcCtD
Loperamide—CALM1—lymph node—colon cancer	0.000567	0.00672	CbGeAlD
Loperamide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00056	0.00354	CcSEcCtD
Loperamide—CYP3A4—digestive system—colon cancer	0.00056	0.00664	CbGeAlD
Loperamide—Gastrointestinal pain—Irinotecan—colon cancer	0.000554	0.0035	CcSEcCtD
Loperamide—CYP2B6—liver—colon cancer	0.000552	0.00655	CbGeAlD
Loperamide—CYP2D6—digestive system—colon cancer	0.000551	0.00653	CbGeAlD
Loperamide—Abdominal pain—Vincristine—colon cancer	0.00055	0.00348	CcSEcCtD
Loperamide—Flatulence—Capecitabine—colon cancer	0.000547	0.00346	CcSEcCtD
Loperamide—Abdominal pain—Irinotecan—colon cancer	0.000535	0.00339	CcSEcCtD
Loperamide—Drowsiness—Methotrexate—colon cancer	0.000529	0.00335	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000524	0.00332	CcSEcCtD
Loperamide—ABCB1—epithelium—colon cancer	0.000521	0.00618	CbGeAlD
Loperamide—Urticaria—Fluorouracil—colon cancer	0.000515	0.00326	CcSEcCtD
Loperamide—Hypersensitivity—Vincristine—colon cancer	0.000512	0.00324	CcSEcCtD
Loperamide—Hypersensitivity—Irinotecan—colon cancer	0.000499	0.00316	CcSEcCtD
Loperamide—Asthenia—Vincristine—colon cancer	0.000499	0.00316	CcSEcCtD
Loperamide—Loss of consciousness—Capecitabine—colon cancer	0.000488	0.00309	CcSEcCtD
Loperamide—Asthenia—Irinotecan—colon cancer	0.000486	0.00308	CcSEcCtD
Loperamide—ABCB1—renal system—colon cancer	0.000483	0.00573	CbGeAlD
Loperamide—Hypersensitivity—Fluorouracil—colon cancer	0.000478	0.00302	CcSEcCtD
Loperamide—Diarrhoea—Vincristine—colon cancer	0.000476	0.00301	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000469	0.00297	CcSEcCtD
Loperamide—Urinary tract disorder—Methotrexate—colon cancer	0.000469	0.00297	CcSEcCtD
Loperamide—Discomfort—Capecitabine—colon cancer	0.000467	0.00296	CcSEcCtD
Loperamide—Urethral disorder—Methotrexate—colon cancer	0.000465	0.00295	CcSEcCtD
Loperamide—Diarrhoea—Irinotecan—colon cancer	0.000463	0.00293	CcSEcCtD
Loperamide—Dry mouth—Capecitabine—colon cancer	0.000462	0.00293	CcSEcCtD
Loperamide—Dizziness—Vincristine—colon cancer	0.00046	0.00291	CcSEcCtD
Loperamide—Pruritus—Fluorouracil—colon cancer	0.000459	0.0029	CcSEcCtD
Loperamide—Erythema multiforme—Methotrexate—colon cancer	0.000449	0.00284	CcSEcCtD
Loperamide—Dizziness—Irinotecan—colon cancer	0.000448	0.00283	CcSEcCtD
Loperamide—Nervous system disorder—Capecitabine—colon cancer	0.000444	0.00281	CcSEcCtD
Loperamide—Diarrhoea—Fluorouracil—colon cancer	0.000444	0.00281	CcSEcCtD
Loperamide—Vomiting—Vincristine—colon cancer	0.000442	0.0028	CcSEcCtD
Loperamide—Skin disorder—Capecitabine—colon cancer	0.00044	0.00279	CcSEcCtD
Loperamide—Rash—Vincristine—colon cancer	0.000438	0.00277	CcSEcCtD
Loperamide—Dermatitis—Vincristine—colon cancer	0.000438	0.00277	CcSEcCtD
Loperamide—Headache—Vincristine—colon cancer	0.000436	0.00276	CcSEcCtD
Loperamide—Vomiting—Irinotecan—colon cancer	0.00043	0.00273	CcSEcCtD
Loperamide—Immune system disorder—Methotrexate—colon cancer	0.000429	0.00271	CcSEcCtD
Loperamide—Dizziness—Fluorouracil—colon cancer	0.000429	0.00271	CcSEcCtD
Loperamide—Rash—Irinotecan—colon cancer	0.000427	0.0027	CcSEcCtD
Loperamide—Dermatitis—Irinotecan—colon cancer	0.000427	0.0027	CcSEcCtD
Loperamide—Headache—Irinotecan—colon cancer	0.000424	0.00269	CcSEcCtD
Loperamide—CYP3A4—liver—colon cancer	0.000417	0.00495	CbGeAlD
Loperamide—Nausea—Vincristine—colon cancer	0.000413	0.00261	CcSEcCtD
Loperamide—Vomiting—Fluorouracil—colon cancer	0.000412	0.00261	CcSEcCtD
Loperamide—CYP2D6—liver—colon cancer	0.00041	0.00487	CbGeAlD
Loperamide—Rash—Fluorouracil—colon cancer	0.000409	0.00259	CcSEcCtD
Loperamide—Dermatitis—Fluorouracil—colon cancer	0.000408	0.00259	CcSEcCtD
Loperamide—Headache—Fluorouracil—colon cancer	0.000406	0.00257	CcSEcCtD
Loperamide—Nausea—Irinotecan—colon cancer	0.000402	0.00255	CcSEcCtD
Loperamide—ABCB1—lymphoid tissue—colon cancer	0.000401	0.00476	CbGeAlD
Loperamide—Dyspepsia—Capecitabine—colon cancer	0.000399	0.00253	CcSEcCtD
Loperamide—ABCB1—digestive system—colon cancer	0.000396	0.0047	CbGeAlD
Loperamide—Gastrointestinal disorder—Capecitabine—colon cancer	0.000391	0.00248	CcSEcCtD
Loperamide—Fatigue—Capecitabine—colon cancer	0.000391	0.00247	CcSEcCtD
Loperamide—Constipation—Capecitabine—colon cancer	0.000388	0.00245	CcSEcCtD
Loperamide—Nausea—Fluorouracil—colon cancer	0.000385	0.00244	CcSEcCtD
Loperamide—Toremifene—ABCB1—colon cancer	0.000375	0.221	CrCbGaD
Loperamide—Gastrointestinal pain—Capecitabine—colon cancer	0.000371	0.00235	CcSEcCtD
Loperamide—ABCB1—bone marrow—colon cancer	0.000365	0.00433	CbGeAlD
Loperamide—Urticaria—Capecitabine—colon cancer	0.00036	0.00228	CcSEcCtD
Loperamide—Abdominal pain—Capecitabine—colon cancer	0.000358	0.00227	CcSEcCtD
Loperamide—ABCB1—vagina—colon cancer	0.00035	0.00415	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000349	0.00221	CcSEcCtD
Loperamide—Discomfort—Methotrexate—colon cancer	0.000348	0.0022	CcSEcCtD
Loperamide—Anaphylactic shock—Methotrexate—colon cancer	0.000337	0.00214	CcSEcCtD
Loperamide—Hypersensitivity—Capecitabine—colon cancer	0.000334	0.00211	CcSEcCtD
Loperamide—Nervous system disorder—Methotrexate—colon cancer	0.000331	0.00209	CcSEcCtD
Loperamide—Fexofenadine—ABCB1—colon cancer	0.000328	0.193	CrCbGaD
Loperamide—Skin disorder—Methotrexate—colon cancer	0.000328	0.00207	CcSEcCtD
Loperamide—Asthenia—Capecitabine—colon cancer	0.000325	0.00206	CcSEcCtD
Loperamide—Pruritus—Capecitabine—colon cancer	0.000321	0.00203	CcSEcCtD
Loperamide—Diarrhoea—Capecitabine—colon cancer	0.00031	0.00196	CcSEcCtD
Loperamide—Somnolence—Methotrexate—colon cancer	0.0003	0.0019	CcSEcCtD
Loperamide—Dizziness—Capecitabine—colon cancer	0.0003	0.0019	CcSEcCtD
Loperamide—Dyspepsia—Methotrexate—colon cancer	0.000297	0.00188	CcSEcCtD
Loperamide—ABCB1—liver—colon cancer	0.000295	0.0035	CbGeAlD
Loperamide—Gastrointestinal disorder—Methotrexate—colon cancer	0.000291	0.00184	CcSEcCtD
Loperamide—Fatigue—Methotrexate—colon cancer	0.000291	0.00184	CcSEcCtD
Loperamide—Vomiting—Capecitabine—colon cancer	0.000288	0.00182	CcSEcCtD
Loperamide—Rash—Capecitabine—colon cancer	0.000286	0.00181	CcSEcCtD
Loperamide—Dermatitis—Capecitabine—colon cancer	0.000285	0.00181	CcSEcCtD
Loperamide—Headache—Capecitabine—colon cancer	0.000284	0.0018	CcSEcCtD
Loperamide—Gastrointestinal pain—Methotrexate—colon cancer	0.000276	0.00175	CcSEcCtD
Loperamide—Nausea—Capecitabine—colon cancer	0.000269	0.0017	CcSEcCtD
Loperamide—Urticaria—Methotrexate—colon cancer	0.000268	0.0017	CcSEcCtD
Loperamide—Abdominal pain—Methotrexate—colon cancer	0.000267	0.00169	CcSEcCtD
Loperamide—Clotrimazole—ABCB1—colon cancer	0.000253	0.149	CrCbGaD
Loperamide—Hypersensitivity—Methotrexate—colon cancer	0.000249	0.00157	CcSEcCtD
Loperamide—Asthenia—Methotrexate—colon cancer	0.000242	0.00153	CcSEcCtD
Loperamide—Pruritus—Methotrexate—colon cancer	0.000239	0.00151	CcSEcCtD
Loperamide—Diarrhoea—Methotrexate—colon cancer	0.000231	0.00146	CcSEcCtD
Loperamide—Haloperidol—ABCB1—colon cancer	0.000228	0.134	CrCbGaD
Loperamide—ABCB1—lymph node—colon cancer	0.000226	0.00268	CbGeAlD
Loperamide—Dizziness—Methotrexate—colon cancer	0.000223	0.00141	CcSEcCtD
Loperamide—Fentanyl—ABCB1—colon cancer	0.000217	0.127	CrCbGaD
Loperamide—Vomiting—Methotrexate—colon cancer	0.000214	0.00136	CcSEcCtD
Loperamide—Rash—Methotrexate—colon cancer	0.000213	0.00135	CcSEcCtD
Loperamide—Dermatitis—Methotrexate—colon cancer	0.000213	0.00135	CcSEcCtD
Loperamide—Headache—Methotrexate—colon cancer	0.000211	0.00134	CcSEcCtD
Loperamide—Nausea—Methotrexate—colon cancer	0.0002	0.00127	CcSEcCtD
Loperamide—Tamoxifen—ABCB1—colon cancer	0.00015	0.0881	CrCbGaD
Loperamide—Methadone—ABCB1—colon cancer	0.000149	0.0874	CrCbGaD
Loperamide—CALM2—Hemostasis—HRAS—colon cancer	1.54e-05	0.000127	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—HRAS—colon cancer	1.54e-05	0.000127	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—EP300—colon cancer	1.51e-05	0.000124	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—PIK3CA—colon cancer	1.5e-05	0.000123	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—PIK3CA—colon cancer	1.5e-05	0.000123	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MYC—colon cancer	1.5e-05	0.000123	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TGFB1—colon cancer	1.5e-05	0.000123	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—PIK3CA—colon cancer	1.49e-05	0.000122	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PPARG—colon cancer	1.48e-05	0.000122	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ABCB1—colon cancer	1.48e-05	0.000122	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—HRAS—colon cancer	1.48e-05	0.000121	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—SRC—colon cancer	1.47e-05	0.000121	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—EGFR—colon cancer	1.47e-05	0.00012	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—TYMS—colon cancer	1.46e-05	0.000119	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PPARG—colon cancer	1.44e-05	0.000119	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—PIK3CA—colon cancer	1.44e-05	0.000118	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—PIK3CA—colon cancer	1.44e-05	0.000118	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—AKT1—colon cancer	1.44e-05	0.000118	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—HRAS—colon cancer	1.44e-05	0.000118	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—VEGFA—colon cancer	1.43e-05	0.000117	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CASP3—colon cancer	1.43e-05	0.000117	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—NRAS—colon cancer	1.41e-05	0.000116	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—AKT1—colon cancer	1.41e-05	0.000116	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PPARG—colon cancer	1.4e-05	0.000115	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PPARG—colon cancer	1.4e-05	0.000115	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—HRAS—colon cancer	1.39e-05	0.000114	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—HRAS—colon cancer	1.39e-05	0.000114	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—KRAS—colon cancer	1.39e-05	0.000114	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CCND1—colon cancer	1.39e-05	0.000114	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HRAS—colon cancer	1.38e-05	0.000113	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CTNNB1—colon cancer	1.37e-05	0.000113	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.37e-05	0.000112	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FGFR3—colon cancer	1.36e-05	0.000112	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—AKT1—colon cancer	1.36e-05	0.000112	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—AKT1—colon cancer	1.36e-05	0.000112	CbGpPWpGaD
Loperamide—CALM3—Disease—PTGS2—colon cancer	1.36e-05	0.000111	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CDKN1A—colon cancer	1.34e-05	0.00011	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HRAS—colon cancer	1.33e-05	0.000109	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HRAS—colon cancer	1.33e-05	0.000109	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FGFR3—colon cancer	1.32e-05	0.000108	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FGFR3—colon cancer	1.32e-05	0.000108	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MYC—colon cancer	1.32e-05	0.000108	CbGpPWpGaD
Loperamide—CALM3—Immune System—CTNNB1—colon cancer	1.32e-05	0.000108	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TGFB1—colon cancer	1.31e-05	0.000108	CbGpPWpGaD
Loperamide—CALM2—Disease—PTGS2—colon cancer	1.31e-05	0.000108	CbGpPWpGaD
Loperamide—CALM1—Disease—PTGS2—colon cancer	1.31e-05	0.000108	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—AKT1—colon cancer	1.31e-05	0.000107	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—EGFR—colon cancer	1.29e-05	0.000106	CbGpPWpGaD
Loperamide—CALM3—Immune System—CDKN1A—colon cancer	1.28e-05	0.000105	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—EP300—colon cancer	1.28e-05	0.000105	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—PIK3CA—colon cancer	1.27e-05	0.000105	CbGpPWpGaD
Loperamide—CALM2—Immune System—CTNNB1—colon cancer	1.27e-05	0.000104	CbGpPWpGaD
Loperamide—CALM1—Immune System—CTNNB1—colon cancer	1.27e-05	0.000104	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—AKT1—colon cancer	1.27e-05	0.000104	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PPARG—colon cancer	1.26e-05	0.000103	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—APC—colon cancer	1.25e-05	0.000103	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—NRAS—colon cancer	1.25e-05	0.000103	CbGpPWpGaD
Loperamide—CALM1—Immune System—CDKN1A—colon cancer	1.24e-05	0.000102	CbGpPWpGaD
Loperamide—CALM2—Immune System—CDKN1A—colon cancer	1.24e-05	0.000102	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—SRC—colon cancer	1.24e-05	0.000102	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TP53—colon cancer	1.23e-05	0.000101	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—AKT1—colon cancer	1.23e-05	0.000101	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—AKT1—colon cancer	1.23e-05	0.000101	CbGpPWpGaD
Loperamide—CALM3—Immune System—EP300—colon cancer	1.22e-05	0.0001	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—AKT1—colon cancer	1.22e-05	9.99e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—KRAS—colon cancer	1.22e-05	9.98e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CTNNB1—colon cancer	1.21e-05	9.96e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—APC—colon cancer	1.21e-05	9.93e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—APC—colon cancer	1.21e-05	9.93e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—NRAS—colon cancer	1.21e-05	9.93e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—NRAS—colon cancer	1.21e-05	9.93e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—VEGFA—colon cancer	1.21e-05	9.92e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—NRAS—colon cancer	1.19e-05	9.8e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—SRC—colon cancer	1.19e-05	9.75e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CDKN1A—colon cancer	1.19e-05	9.73e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—EP300—colon cancer	1.18e-05	9.7e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—EP300—colon cancer	1.18e-05	9.7e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—HRAS—colon cancer	1.18e-05	9.67e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—AKT1—colon cancer	1.18e-05	9.67e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—AKT1—colon cancer	1.18e-05	9.67e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—BRAF—colon cancer	1.18e-05	9.65e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CTNNB1—colon cancer	1.17e-05	9.64e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CTNNB1—colon cancer	1.17e-05	9.64e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTGS2—colon cancer	1.17e-05	9.58e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—SRC—colon cancer	1.15e-05	9.43e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—SRC—colon cancer	1.15e-05	9.43e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CDKN1A—colon cancer	1.15e-05	9.41e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CDKN1A—colon cancer	1.15e-05	9.41e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—NRAS—colon cancer	1.14e-05	9.38e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—EGFR—colon cancer	1.14e-05	9.36e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—BRAF—colon cancer	1.14e-05	9.34e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—BRAF—colon cancer	1.14e-05	9.34e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTGS2—colon cancer	1.14e-05	9.32e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—EP300—colon cancer	1.13e-05	9.26e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PIK3CA—colon cancer	1.12e-05	9.17e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MYC—colon cancer	1.11e-05	9.13e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TGFB1—colon cancer	1.11e-05	9.11e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—NRAS—colon cancer	1.11e-05	9.08e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—NRAS—colon cancer	1.11e-05	9.08e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—EGFR—colon cancer	1.1e-05	9.05e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—EGFR—colon cancer	1.1e-05	9.05e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTGS2—colon cancer	1.1e-05	9.02e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTGS2—colon cancer	1.1e-05	9.02e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—SRC—colon cancer	1.1e-05	9e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PPARG—colon cancer	1.09e-05	8.98e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—EP300—colon cancer	1.09e-05	8.96e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—EP300—colon cancer	1.09e-05	8.96e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—EGFR—colon cancer	1.09e-05	8.93e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—colon cancer	1.08e-05	8.87e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—KRAS—colon cancer	1.08e-05	8.84e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—SRC—colon cancer	1.06e-05	8.71e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—SRC—colon cancer	1.06e-05	8.71e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—NRAS—colon cancer	1.06e-05	8.66e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—KRAS—colon cancer	1.04e-05	8.55e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—KRAS—colon cancer	1.04e-05	8.55e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—EGFR—colon cancer	1.04e-05	8.55e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—AKT1—colon cancer	1.04e-05	8.54e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—HRAS—colon cancer	1.03e-05	8.48e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PPARG—colon cancer	1.03e-05	8.47e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KRAS—colon cancer	1.03e-05	8.43e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—NRAS—colon cancer	1.02e-05	8.38e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—NRAS—colon cancer	1.02e-05	8.38e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—EGFR—colon cancer	1.01e-05	8.27e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—EGFR—colon cancer	1.01e-05	8.27e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—PIK3CA—colon cancer	9.9e-06	8.12e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTGS2—colon cancer	9.89e-06	8.11e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—KRAS—colon cancer	9.84e-06	8.08e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MYC—colon cancer	9.84e-06	8.07e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—TGFB1—colon cancer	9.81e-06	8.05e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—EP300—colon cancer	9.71e-06	7.97e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ABCB1—colon cancer	9.7e-06	7.96e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—EGFR—colon cancer	9.62e-06	7.89e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—PIK3CA—colon cancer	9.57e-06	7.85e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—PIK3CA—colon cancer	9.57e-06	7.85e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—TYMS—colon cancer	9.52e-06	7.81e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—KRAS—colon cancer	9.52e-06	7.81e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—KRAS—colon cancer	9.52e-06	7.81e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MYC—colon cancer	9.51e-06	7.81e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MYC—colon cancer	9.51e-06	7.81e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—TGFB1—colon cancer	9.49e-06	7.79e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—TGFB1—colon cancer	9.49e-06	7.79e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—EP300—colon cancer	9.45e-06	7.76e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PIK3CA—colon cancer	9.45e-06	7.75e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—EGFR—colon cancer	9.31e-06	7.63e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—EGFR—colon cancer	9.31e-06	7.63e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—HRAS—colon cancer	9.16e-06	7.51e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—EP300—colon cancer	9.14e-06	7.5e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—EP300—colon cancer	9.14e-06	7.5e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—colon cancer	9.14e-06	7.5e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—AKT1—colon cancer	9.13e-06	7.49e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—KRAS—colon cancer	9.09e-06	7.46e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—PIK3CA—colon cancer	9.04e-06	7.42e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—HRAS—colon cancer	8.86e-06	7.27e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—HRAS—colon cancer	8.86e-06	7.27e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CASP3—colon cancer	8.82e-06	7.24e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—KRAS—colon cancer	8.79e-06	7.21e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—KRAS—colon cancer	8.79e-06	7.21e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—PIK3CA—colon cancer	8.75e-06	7.18e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—PIK3CA—colon cancer	8.75e-06	7.18e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HRAS—colon cancer	8.74e-06	7.17e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTGS2—colon cancer	8.61e-06	7.07e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCND1—colon cancer	8.59e-06	7.04e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CASP3—colon cancer	8.53e-06	7e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CASP3—colon cancer	8.53e-06	7e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CTNNB1—colon cancer	8.5e-06	6.98e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—HRAS—colon cancer	8.37e-06	6.86e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PIK3CA—colon cancer	8.35e-06	6.85e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CDKN1A—colon cancer	8.31e-06	6.81e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCND1—colon cancer	8.31e-06	6.81e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCND1—colon cancer	8.31e-06	6.81e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CTNNB1—colon cancer	8.23e-06	6.75e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CTNNB1—colon cancer	8.23e-06	6.75e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—EP300—colon cancer	8.22e-06	6.75e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTGS2—colon cancer	8.12e-06	6.66e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—HRAS—colon cancer	8.09e-06	6.64e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—HRAS—colon cancer	8.09e-06	6.64e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—AKT1—colon cancer	8.09e-06	6.63e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PIK3CA—colon cancer	8.08e-06	6.63e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PIK3CA—colon cancer	8.08e-06	6.63e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CDKN1A—colon cancer	8.04e-06	6.59e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CDKN1A—colon cancer	8.04e-06	6.59e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EP300—colon cancer	7.9e-06	6.48e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—AKT1—colon cancer	7.82e-06	6.42e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—AKT1—colon cancer	7.82e-06	6.42e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—HRAS—colon cancer	7.73e-06	6.34e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—AKT1—colon cancer	7.72e-06	6.33e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SRC—colon cancer	7.69e-06	6.31e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EP300—colon cancer	7.65e-06	6.27e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EP300—colon cancer	7.65e-06	6.27e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—colon cancer	7.49e-06	6.14e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—HRAS—colon cancer	7.47e-06	6.13e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—HRAS—colon cancer	7.47e-06	6.13e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SRC—colon cancer	7.44e-06	6.1e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SRC—colon cancer	7.44e-06	6.1e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NRAS—colon cancer	7.39e-06	6.07e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—AKT1—colon cancer	7.39e-06	6.06e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—colon cancer	7.24e-06	5.94e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—colon cancer	7.24e-06	5.94e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PIK3CA—colon cancer	7.19e-06	5.89e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—EP300—colon cancer	7.16e-06	5.88e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NRAS—colon cancer	7.15e-06	5.87e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NRAS—colon cancer	7.15e-06	5.87e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—AKT1—colon cancer	7.15e-06	5.86e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—AKT1—colon cancer	7.15e-06	5.86e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PIK3CA—colon cancer	6.99e-06	5.74e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MYC—colon cancer	6.89e-06	5.65e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TGFB1—colon cancer	6.87e-06	5.64e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—AKT1—colon cancer	6.82e-06	5.6e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PIK3CA—colon cancer	6.76e-06	5.55e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PIK3CA—colon cancer	6.76e-06	5.55e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—EP300—colon cancer	6.75e-06	5.54e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPARG—colon cancer	6.75e-06	5.53e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EGFR—colon cancer	6.74e-06	5.53e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MYC—colon cancer	6.66e-06	5.47e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MYC—colon cancer	6.66e-06	5.47e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TGFB1—colon cancer	6.65e-06	5.45e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TGFB1—colon cancer	6.65e-06	5.45e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—AKT1—colon cancer	6.6e-06	5.41e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—AKT1—colon cancer	6.6e-06	5.41e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EGFR—colon cancer	6.52e-06	5.35e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EGFR—colon cancer	6.52e-06	5.35e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KRAS—colon cancer	6.36e-06	5.22e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KRAS—colon cancer	6.16e-06	5.05e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KRAS—colon cancer	6.16e-06	5.05e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CA—colon cancer	6.08e-06	4.99e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—AKT1—colon cancer	5.87e-06	4.82e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CA—colon cancer	5.85e-06	4.8e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—AKT1—colon cancer	5.71e-06	4.69e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—colon cancer	5.66e-06	4.64e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CA—colon cancer	5.66e-06	4.64e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CA—colon cancer	5.66e-06	4.64e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—AKT1—colon cancer	5.53e-06	4.53e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—AKT1—colon cancer	5.53e-06	4.53e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—colon cancer	5.47e-06	4.49e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—colon cancer	5.47e-06	4.49e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HRAS—colon cancer	5.41e-06	4.44e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS2—colon cancer	5.31e-06	4.35e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CA—colon cancer	5.3e-06	4.35e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HRAS—colon cancer	5.23e-06	4.29e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HRAS—colon cancer	5.23e-06	4.29e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CA—colon cancer	4.99e-06	4.1e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—AKT1—colon cancer	4.97e-06	4.08e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AKT1—colon cancer	4.78e-06	3.92e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKT1—colon cancer	4.62e-06	3.79e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKT1—colon cancer	4.62e-06	3.79e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—EP300—colon cancer	4.41e-06	3.62e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AKT1—colon cancer	4.33e-06	3.55e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AKT1—colon cancer	4.08e-06	3.35e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CA—colon cancer	3.27e-06	2.68e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AKT1—colon cancer	2.67e-06	2.19e-05	CbGpPWpGaD
